Please upgrade your browser.
Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine
Advances in nephron-sparing surgery, laparoscopic approaches, and novel targeted therapies have dramatically improved the outcomes for patients with renal-cell carcinoma. Despite these advances, adjuvant treatment options following surgery are needed, and one approach that was shown to be successful in a previous multicenter phase III trial was an autologous tumor-based vaccine.
Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer
A 74-year-old male is admitted to hospital for dyspnoea. Findings from chest x-ray, computed tomography, and colonoscopy are described; images provided.
. . . chemicals poured into sunscreen products are equally dubious. They include:TEA, DEA, MEA (tri-, di- and mono- ethaloamines). These chemicals can cause liver and kidney cancer.
Seattle Genetics has two proprietary ADCs in the clinic, one in late stage trials for Hodgkins Lymphoma and a second in early stage trials for non-Hodgkins Lymphoma and Renal Cell Carcinoma.
A CANCER patient from Yorkshire has become the first in the world to trial a new drug experts hope will become part of a new generation of treatments against the disease.
Not only did Bob meet Elvis Presley, he also ended up with a bottle of the King's Vaseline Hair Tonic. Inspired by this anecdote, I asked readers to send me their accounts of encounters with the famous.
A CANCER patient last night said he felt "completely abandoned" after health chiefs refused to pay for a new drug which could prolong his life.
Proposals to use these agents as neoadjuvant therapy have generated significant controversy, Dr. Van Poppel said.
Agent shows high preoperative sensitivity, specificity, data indicate.
|Powered by NeonCRM|